JAG1 and neoplasm: The angiogenic capacity of the secretome was examined by using tube-formation assays.<h4>Results</h4>Among patients receiving bevacizumab, those with low tumour JAG1 expression exhibited longer progression-free survival and time to progression than patients with high JAG1 expression.